Biocon posts strong Q3FY26 growth, boosted by biosimilars & generics
Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
Occlutech develops, manufactures, and commercialises medical devices for congenital heart disease, stroke prevention, and heart failure
The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
The milestone means more than 1,000 men are now enrolled across both Phase 3 programs
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
The revenues this quarter are in line with the outlook we envisaged for the year
Subscribe To Our Newsletter & Stay Updated